Article from Drugs.com
FDA Clears Jardiance for Use in Chronic Kidney Disease (CKD)
In September, the FDA cleared Jardiance (empagliflozin), from Boehringer Ingelheim and Eli Lilly, to reduce the risk of further worsening of kidney disease, end-stage kidney disease (ESKD), death due to cardiovascular disease, and hospitalization in adults with chronic kidney disease (CKD).
This is the fourth approved use for Jardiance, a sodium glucose co-transporter-2 (SGLT2) inhibitor also used for cardiovascular risk reduction, heart failure, and to improve glycemic (blood sugar) control in type 2 diabetes.
Approval was supported by the Phase 3 EMPA-KIDNEY study with over 6,600 patients. Jardiance, in addition to standard care, demonstrated a 28% relative risk reduction (HR=0.72; 95% CI 0.64 to 0.82; P<0.0001) compared with placebo, for the composite primary endpoint of kidney disease progression or cardiovascular death. A 14% relative risk reduction in first and recurrent hospitalization, a key secondary endpoint, was also seen vs. placebo (HR=0.86; 95% CI 0.78 to 0.95; p=0.0025).
The recommended dose for this use is 10 mg orally once daily in the morning, taken with or without